Debate Over U.S. Antidepressant Use Highlights Overprescription and Access Challenges

In the United States, about one-sixth of adults fill prescriptions for antidepressants, a figure that has drawn scrutiny from health officials. Selective serotonin reuptake inhibitors, first introduced in the late 1980s, remain the most common class, but they are intended mainly for moderate or severe depression, not for fleeting low moods. The bulk of these prescriptions are written by primary-care clinicians, who often lack the time and resources to offer alternatives such as psychotherapy, especially in settings without integrated behavioral health teams.

The COVID-19 pandemic accelerated telehealth use, expanding medication access but also allowing patients to bypass specialist evaluation. HHS Secretary Robert F. Kennedy Jr. launched a campaign in May 2026 urging physicians to prioritize non-pharmacologic treatments when feasible. The author, drawing on three decades of psychiatric practice and former leadership at North Dakota’s Department of Human Services, acknowledges both the benefits of antidepressants for severe cases and the overuse in milder situations, attributing the imbalance to broader systemic issues. He also highlights that tapering off long-term medication can trigger withdrawal symptoms for a minority, underscoring the need for careful clinical guidance.